<div id="readability-page-1"><p>Leerink Partners analyst Jeffrey La Rosa has maintained their bullish  stance on <span>SNTI</span> stock, giving a Buy rating on December 10.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Jeffrey La Rosa has given his Buy rating due to a combination of factors that highlight the promising potential of Senti Biosciences’ lead therapy, SENTI-202, in treating relapsed or refractory acute myeloid leukemia (r/r AML). The recent Phase 1 update for SENTI-202 demonstrated encouraging results, particularly in terms of efficacy and safety, which La Rosa believes de-risk further investment in the program. Despite the small sample size, the therapy showed a favorable emerging efficacy signal with strong indicators of overall survival, such as high rates of MRD-negativity and competitive duration-of-response.<br/>Additionally, SENTI-202’s positive safety profile, characterized by mild acute immune-related toxicities and rapid hematopoietic stem cell recovery, further supports its potential advantage over existing treatment options. The therapy’s unique logic-gate-CARs and NK cell chassis contribute to its differentiated safety and efficacy, potentially allowing for broader patient eligibility. However, La Rosa notes that the primary risk for Senti Biosciences is financial, given their current cash position, which underscores the importance of securing additional funding to advance the program.</p> <p>In another report released on December 10, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.</p> </div>

<p>Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial Risks</p>